Insider

Zoetis Inc.

ZTS Health Care · 3 analyses · 3 expectations tracked

Zoetis reported $2.4B in revenue (-1.3% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 3 open management expectations for this company.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Zoetis reports third-quarter 2026 results

In the third quarter of 2026, Zoetis revenue fell 1.3% to $2,391 million, and net income declined 18% compared to the same period last year. Financial results reflect operational changes and currency fluctuations.

· Zoetis Inc.

Company history

October 2026

Zoetis Inc.: 10 recorded developments from 4 official sources in 2026-10.

  • 2026-10-08: Zoetis Inc. has declared a dividend of $0.53 per share for the fourth quarter of 2026. Source
  • 2026-10-08: The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. Source
  • 2026-10-08: Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Source
  • 2026-10-08: On October 8, 2026, the Company declared a dividend of $0.53 per share for the fourth quarter of 2026. Source
  • 2026-10-08: The dividend will be paid on December 1, 2026, to all holders of record of the Company's common stock as of the close of business on October 30, 2026. Source
  • 2026-10-13: The form of indemnification agreement that Zoetis Inc. will enter into with Ms. Knobloch was previously filed by the Company as Exhibit 10.19 to Amendment No. 4 to the Company’s Registration Statement on Form S-1 (File No. 333-183254), as originally filed with the SEC on August 13, 2012, Source
  • 2026-10-13: On October 13, 2026, Zoetis Inc. announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. Source
  • 2026-10-13: Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Source
  • 2026-10-13: On October 13, 2026, Zoetis Inc. issued a press release announcing the appointment of Ms. Iris Knobloch to the Board. Source
  • 2026-10-13: Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between Zoetis Inc. and Ms. Knobloch that would be reportable under Item 404(a) Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 5, 2026. SEC

LatestEarlierChange
Revenue quarter$2.4B$2.4B-1.3%
Net income quarter$591M$721M-18.0%
Diluted EPS quarter$1.44$1.63-11.7%
Dividends per share quarter$0.00$0.00—
Operating cash flow year to date$1.9B$2.1B-8.6%
Cash and cash equivalents balance$1.3B$2.5B-45.6%
Long-term debt balance$8.3B$9B-8.2%

Next results expected around February 4, 2027 (estimate: the quarter ending about December 30, 2026 plus the 36 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

2.3Q4 '24*2.2Q1 '252.5Q2 '252.4Q3 '252.4Q4 '25*2.3Q1 '262.5Q2 '262.4Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Zoetis Inc. ZTS$2.4B-1.3%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company remains on track for expected 2026 product approvals.

    Said November 5, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Select product approvals previously anticipated in 2027 are now expected in the fourth quarter of 2026.

    Said November 5, 2026 · Period named: Q4 2026 · Source · Our article

    Not yet checked against later reports.

  • Convenia RTU for Dogs is expected to be available to veterinarians.

    Said November 5, 2026 · Period named: first quarter of 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 13, 2026Director or officer departure or appointment (8-K item 5.02)8-K
August 6, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock38,528,306$2,690,431,629-2.3%Q3 2026
State Street19,705,376$1,376,026,406+0.2%Q3 2026
Geode Capital Management13,272,635$923,707,381-0.1%Q3 2026
Norges Bank (Norway's sovereign fund)4,689,847$337,012,405—Q2 2026
Citadel Advisors1,939,150$135,410,844-39.2%Q3 2026
Renaissance Technologies1,660,500$115,952,715+18.3%Q3 2026
Capital Research Global Investors980,811$70,481,078-30.4%Q2 2026
Fidelity (FMR)925,614$64,635,660+143.2%Q3 2026
D. E. Shaw & Co.688,352$48,067,620+28.1%Q3 2026
Bridgewater Associates476,249$33,256,468+254.9%Q3 2026
Millennium Management409,865$28,620,873-77.4%Q3 2026
Wellington Management172,349$12,035,131-98.2%Q3 2026
Two Sigma Investments168,491$11,765,727-56.4%Q3 2026
Soros Fund Management27,808$1,998,283—Q2 2026
T. Rowe Price799,492$55,829-29.8%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.